Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma

Aniko Fodor, M. Molnár, L. Krenács, E. Bagdi, Judit Csomor, A. Matolcsy, J. Demeter

Research output: Article

6 Citations (Scopus)

Abstract

Splenic marginal zone lymphoma is a rare disease, accounting for 1% of all lymphomas. We reviewed our single center experience of 13 patients with splenic marginal zone lymphoma (SMZL). Based on the prognostic model developed by Intergruppo Italiano Linfomi, 31% (4/13) of our patients had good, 38% (5/13) had intermediate and 31% (4/13) had a poor prognosis. The presence of two out of three prognostic factors (anemia, elevated LDH, low serum albumin) assignes the patient into the high risk category. In patients with anemia and an elevated LDH due to hemolysis, the outcome seems to be especially poor. Three out of 13 (23%) cases were complicated by autoimmune hemolytic anemia. All patients with autoimmune hemolytic anaemia (AIHA) died 7-28 months after the diagnosis. The mean follow-up time of those nine patients who are still alive is longer than 5 years (36-100 months). Patients with AIHA had significantly (p∈

Original languageEnglish
Pages (from-to)597-603
Number of pages7
JournalPathology and Oncology Research
Volume15
Issue number4
DOIs
Publication statusPublished - dec. 2009

Fingerprint

Autoimmune Hemolytic Anemia
Lymphoma
Anemia
Rare Diseases
Hemolysis
Serum Albumin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

@article{2ecef2d4839848bb9f5cb71c27939904,
title = "Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma",
abstract = "Splenic marginal zone lymphoma is a rare disease, accounting for 1{\%} of all lymphomas. We reviewed our single center experience of 13 patients with splenic marginal zone lymphoma (SMZL). Based on the prognostic model developed by Intergruppo Italiano Linfomi, 31{\%} (4/13) of our patients had good, 38{\%} (5/13) had intermediate and 31{\%} (4/13) had a poor prognosis. The presence of two out of three prognostic factors (anemia, elevated LDH, low serum albumin) assignes the patient into the high risk category. In patients with anemia and an elevated LDH due to hemolysis, the outcome seems to be especially poor. Three out of 13 (23{\%}) cases were complicated by autoimmune hemolytic anemia. All patients with autoimmune hemolytic anaemia (AIHA) died 7-28 months after the diagnosis. The mean follow-up time of those nine patients who are still alive is longer than 5 years (36-100 months). Patients with AIHA had significantly (p∈",
keywords = "Autoimmune hemolytic anemia, Outcome, Prognosis, Splenic marginal zone lymphoma",
author = "Aniko Fodor and M. Moln{\'a}r and L. Kren{\'a}cs and E. Bagdi and Judit Csomor and A. Matolcsy and J. Demeter",
year = "2009",
month = "12",
doi = "10.1007/s12253-009-9159-8",
language = "English",
volume = "15",
pages = "597--603",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma

AU - Fodor, Aniko

AU - Molnár, M.

AU - Krenács, L.

AU - Bagdi, E.

AU - Csomor, Judit

AU - Matolcsy, A.

AU - Demeter, J.

PY - 2009/12

Y1 - 2009/12

N2 - Splenic marginal zone lymphoma is a rare disease, accounting for 1% of all lymphomas. We reviewed our single center experience of 13 patients with splenic marginal zone lymphoma (SMZL). Based on the prognostic model developed by Intergruppo Italiano Linfomi, 31% (4/13) of our patients had good, 38% (5/13) had intermediate and 31% (4/13) had a poor prognosis. The presence of two out of three prognostic factors (anemia, elevated LDH, low serum albumin) assignes the patient into the high risk category. In patients with anemia and an elevated LDH due to hemolysis, the outcome seems to be especially poor. Three out of 13 (23%) cases were complicated by autoimmune hemolytic anemia. All patients with autoimmune hemolytic anaemia (AIHA) died 7-28 months after the diagnosis. The mean follow-up time of those nine patients who are still alive is longer than 5 years (36-100 months). Patients with AIHA had significantly (p∈

AB - Splenic marginal zone lymphoma is a rare disease, accounting for 1% of all lymphomas. We reviewed our single center experience of 13 patients with splenic marginal zone lymphoma (SMZL). Based on the prognostic model developed by Intergruppo Italiano Linfomi, 31% (4/13) of our patients had good, 38% (5/13) had intermediate and 31% (4/13) had a poor prognosis. The presence of two out of three prognostic factors (anemia, elevated LDH, low serum albumin) assignes the patient into the high risk category. In patients with anemia and an elevated LDH due to hemolysis, the outcome seems to be especially poor. Three out of 13 (23%) cases were complicated by autoimmune hemolytic anemia. All patients with autoimmune hemolytic anaemia (AIHA) died 7-28 months after the diagnosis. The mean follow-up time of those nine patients who are still alive is longer than 5 years (36-100 months). Patients with AIHA had significantly (p∈

KW - Autoimmune hemolytic anemia

KW - Outcome

KW - Prognosis

KW - Splenic marginal zone lymphoma

UR - http://www.scopus.com/inward/record.url?scp=75049083589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75049083589&partnerID=8YFLogxK

U2 - 10.1007/s12253-009-9159-8

DO - 10.1007/s12253-009-9159-8

M3 - Article

C2 - 19343544

AN - SCOPUS:75049083589

VL - 15

SP - 597

EP - 603

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 4

ER -